Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05PIX
|
|||
| Former ID |
DIB001583
|
|||
| Drug Name |
CG-400549
|
|||
| Synonyms |
CG-400329; CG-400462; CG-400587; Bacterial enoyl-ACP reductase inhibitors, CrystalGenomics; FabI inhibitors (antibacterial), CrystalGenomics; FabK inhibitors (bacterial infections, oral), CrystalGenomics
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Phase 2 | [1] | |
| Company |
Cg pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N2O2S
|
|||
| Canonical SMILES |
CC1=C(C=CC=C1N)CN2C=CC(=CC2=O)OCCC3=CC=CS3
|
|||
| InChI |
1S/C19H20N2O2S/c1-14-15(4-2-6-18(14)20)13-21-9-7-16(12-19(21)22)23-10-8-17-5-3-11-24-17/h2-7,9,11-12H,8,10,13,20H2,1H3
|
|||
| InChIKey |
YCLREGRRHGLOAK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 934628-27-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Enoyl ACP reductase (Stap-coc fabI) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Fatty acid biosynthesis | |||
| Biotin metabolism | ||||
| Metabolic pathways | ||||
| Fatty acid metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01593761) Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus. U.S. National Institutes of Health. | |||
| REF 2 | In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.